| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Bacterial cell membrane (glycerol phosphates). Octenidine's two cationic centers bind to the negatively charged components of the cell envelope, causing loss of membrane integrity and leakage of intracellular contents. It also inhibits biofilm-associated gene expression and disrupts biofilm formation.
|
|---|---|
| ln Vitro |
Against Gram-negative bacteria that are resistant to many drugs, octenidine exhibits antibacterial efficacy [1]. Under conditions of extended exposure, Escherichia coli Pseudomonas aeruginosa WT CTX-M-1 CTX-M-15 NDM-1 VIM-15 WT PER-1 VEB-1 OprD VIM-2 MIC (mg/L) 0.5 2.5 1.2 5 2.5 10 40 40 40 40 40 Octenidine (0-20 hours) can retard Pseudomonas aeruginosa development [2].
Octenidine exhibits antimicrobial activity against multidrug-resistant Gram-negative pathogens. MIC values: E. coli WT 0.5 mg/L, CTX-M-1 2.5 mg/L, CTX-M-15 1.2 mg/L, NDM-1 5 mg/L, VIM-15 2.5 mg/L; P. aeruginosa WT 10 mg/L, PER-1 40 mg/L, VEB-1 40 mg/L, OprD 40 mg/L, VIM-2 40 mg/L. It inhibits biofilm gene expression and destroys biofilm formation. |
| ln Vivo |
Octenidine suppresses methicillin-resistant Staphylococcus aureus (MRSA) and decreases the amount of germs on mouse wounds [3].
In vivo, Octenidine reduces bacterial counts on mice wounds and inhibits meticillin-resistant Staphylococcus aureus (MRSA). In a mouse wound model inoculated with MRSA, Octenidine accelerated healing and reduced bacterial counts by >3.6 log cfu/g relative to PBS control. It exhibited lower burden of inflammatory cells, more mature collagen fibres and well-defined epithelialisation, and inhibited expression of MRSA biofilm genes by nearly 100%. |
| Enzyme Assay |
Biochemical membrane disruption assays use liposomes or bacterial membrane preparations. Octenidine is incubated with lipopolysaccharide (LPS) or phospholipid vesicles, and membrane permeability is measured by leakage of fluorescent dyes (calcein, carboxyfluorescein). Binding affinity to LPS is assessed by isothermal titration calorimetry or fluorescence polarization.
|
| Cell Assay |
G Antimicrobial susceptibility testing uses broth microdilution in Mueller-Hinton broth. Bacterial strains (E. coli, P. aeruginosa, S. aureus including MRSA) are adjusted to 10^5 CFU/mL and treated with two-fold serial dilutions of Octenidine. MIC values are determined after 18-24 hours. Biofilm inhibition is assessed using crystal violet staining and confocal microscopy.
|
| Animal Protocol |
Animal/Disease Models: Mice (six mm punched full-thickness wound inoculated with MRSA suspension) [3]
Doses: Route of Administration: Once administered 24 hrs (hrs (hours)) after injury Experimental Results: Accelerated healing and reduction of >3.6 log cfu/g bacterial counts Wound vs. PBS-treated control. Demonstrates lower inflammatory cell burden, more mature collagen fibers, and well-defined epithelialization. Inhibits the expression of MRSA and its biofilm genes by nearly 100%. Mouse wound infection models use a six-millimetre punch full-thickness wound inoculated with MRSA suspension. Octenidine is administered once 24 hours post-wounding. Efficacy is assessed by bacterial counts (CFU/g tissue), histological analysis of inflammatory cells, collagen fibres, and epithelialisation, and biofilm gene expression by RT-qPCR. |
| References |
|
| Additional Infomation |
Octenidine is a dihydropyridine compound. Octenidine is currently being studied in the clinical trial NCT02697162 (antimicrobial coated intermittent urinary catheter).
|
| Molecular Formula |
C36H64CL2N4
|
|---|---|
| Molecular Weight |
623.83
|
| Exact Mass |
550.497
|
| CAS # |
71251-02-0
|
| Related CAS # |
Octenidine dihydrochloride;70775-75-6
|
| PubChem CID |
51167
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.94 g/cm3
|
| Boiling Point |
609.3ºC at 760 mmHg
|
| Melting Point |
215-217ºC
|
| Index of Refraction |
1.518
|
| LogP |
9.633
|
| tPSA |
34.58
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
40
|
| Complexity |
691
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/N=C1C=CN(C=C\1)CCCCCCCCCCN(C=C/2)C=CC2=N\CCCCCCCC.Cl.Cl
|
| InChi Key |
ZVXNYZWXUADSRV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C36H62N4/c1-3-5-7-9-15-19-27-37-35-23-31-39(32-24-35)29-21-17-13-11-12-14-18-22-30-40-33-25-36(26-34-40)38-28-20-16-10-8-6-4-2/h23-26,31-34H,3-22,27-30H2,1-2H3
|
| Chemical Name |
N-octyl-1-[10-(4-octyliminopyridin-1-yl)decyl]pyridin-4-imine
|
| Synonyms |
OCT Octenidine 2HCl Octenidine Dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6030 mL | 8.0150 mL | 16.0300 mL | |
| 5 mM | 0.3206 mL | 1.6030 mL | 3.2060 mL | |
| 10 mM | 0.1603 mL | 0.8015 mL | 1.6030 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.